Abstract
In a randomized trial among African women with recurrent genital herpes, episodic acyclovir therapy resulted in modestly greater likelihood of lesion healing (hazard ratio [HR] = 1.48, P = 0.098; mean, 5.1 vs. 6.0 days) and cessation of herpes simplex virus shedding (HR = 1.88, P = 0.008; mean, 3.0 vs. 5.0 days) compared with placebo, similar to results of studies in high-income countries (ClinicalTrials.gov registration NCT00808405).
Publication types
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
MeSH terms
-
Acyclovir / therapeutic use*
-
Adult
-
Antiviral Agents / therapeutic use*
-
DNA, Viral / genetics
-
Double-Blind Method
-
Female
-
HIV Seronegativity
-
HIV-1 / immunology
-
HIV-1 / isolation & purification
-
Herpes Genitalis / drug therapy*
-
Herpes Genitalis / genetics
-
Herpes Genitalis / virology
-
Herpesvirus 2, Human / drug effects
-
Herpesvirus 2, Human / immunology*
-
Herpesvirus 2, Human / isolation & purification
-
Humans
-
Kaplan-Meier Estimate
-
Middle Aged
-
Recurrence
-
Seroepidemiologic Studies
-
South Africa / epidemiology
-
Ulcer / drug therapy*
-
Ulcer / genetics
-
Ulcer / virology
-
Virus Shedding / drug effects
-
Zambia / epidemiology
Substances
-
Antiviral Agents
-
DNA, Viral
-
Acyclovir
Associated data
-
ClinicalTrials.gov/NCT00808405